GSK and Hengrui Pharma officially enter agreement to develop up to 12 innovative medicines

GSK announces that they have recently entered into agreements with Hengrui Pharma to develop up to 12 innovative medicines. GSK will pay $500 million in upfront fees across the agreements.

Note that the agreements include an exclusive worldwide license for a potential best-in-class, PDE3/4 inhibitor in clinical development for the treatment of chronic obstructive pulmonary disease as an add-on maintenance treatment, irrespective of background therapy.

This agreement also include a pioneering scaled collaboration to generate up to 11 programmes in addition to HRS-9821, each with its own financial structure. Hengrui Pharma will lead the development of these programmes up to completion of phase I trials, including patients outside of China. GSK will have the exclusive option to further develop and commercialise each programme worldwide, at the end of phase I or earlier at GSK’s election, as well as certain programme substitution rights.

Tony Wood, Chief Scientific Officer, GSK said: “We’re delighted to announce these exciting agreements with Hengrui Pharma which complement our already-extensive pipeline. This deal reflects our strategic investment in programmes that address validated targets, increasing the likelihood of success, and with the option to advance those assets with the greatest potential for patient impact.”

Frank Jiang, Executive Vice President and Chief Strategy Officer of Hengrui Pharma, said: “This strategic collaboration with GSK marks yet another significant milestone in Hengrui’s globalisation journey and our mission to innovate and deliver higher-quality, cutting-edge therapies for patients worldwide. GSK brings additional R&D expertise, a robust global clinical network, and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programs to overseas markets, potentially delivering breakthrough treatments to patients globally.”

---

---

Related Topics and Keywords

GSK, hengrui pharma, Immunology & Inflammation and Oncology, respiratory